Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in moderate to severe rotator cuff tendinopathy
NCT05569174Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in rotator cuff tendinopathy (RCT), sponsored by Novartis. Started Dec 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
rotator cuff tendinopathy (RCT)
Beyond the preview
Go deeper on NCT05569174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569174.